← Back to news
September 18, 2026
Trump Administration Considers Looser Rules for Pharma Deals with China
- New Treasury Department rules could permit U.S. pharmaceutical companies to license drugs from Chinese firms.
- Licensing deals with China were valued at $115 billion last year, highlighting U.S. reliance on Chinese biotech.
- Some lawmakers advocate for stricter investment restrictions to prevent strategic dependence on China for new medicines.
Read the news this way every day.
Concur organizes political reporting into clear stories and shows the sources behind each one.
Free. No ads.
2 Sources
- US weighs allowing most pharma licensing deals with China, sources saySep 18, 2026 at 10:10 AM · Reuters
- America warned it is becoming dangerously reliant on China for new medicinesSep 18, 2026 at 12:37 PM · Independent